Skip to main
MNKD

MannKind (MNKD) Stock Forecast & Price Target

MannKind (MNKD) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 29%
Buy 57%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

MannKind is positioned for growth in the biopharmaceutical market with a strong product portfolio and promising developments in their pipeline, particularly in the pediatric and orphan lung disease markets. Their strategic partnerships and focus on innovation and convenience give them a competitive edge, but delays and potential competition are potential risks to consider. Effective execution in clinical trials and regulatory processes will be crucial for the company's success in commercializing their products.

Bears say

MannKind is facing multiple risks such as commercial execution, clinical trials, and regulatory hurdles, which may hinder its ability to achieve its 12-month price target of $11. Additionally, the company's diverse pipeline may bring long-term growth opportunities, but carries risk as well. Competition from well-capitalized companies and potential challenges in the supply chain may also pose risks to MannKind's future market share and pricing power. Overall, the company's innovative dry powder drug delivery approach is a strong advantage, but it remains to be seen whether it will be enough to overcome the numerous risks that the company faces.

MannKind (MNKD) has been analyzed by 7 analysts, with a consensus rating of Buy. 29% of analysts recommend a Strong Buy, 57% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of MannKind and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MannKind (MNKD) Forecast

Analysts have given MannKind (MNKD) a Buy based on their latest research and market trends.

According to 7 analysts, MannKind (MNKD) has a Buy consensus rating as of May 1, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MannKind (MNKD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.